电邮这篇文章 Chronic obstructive pulmonary disease exacerbation. Do we use all possibilities of outpatient therapy?
- 作者: Leshchenko IV1,2
-
隶属关系:
- Уральская государственная медицинская академия Минздрава России
- Медицинское объединение "Новая больница", Екатеринбург
- 期: 卷 85, 编号 10 (2013)
- 页面: 83-87
- 栏目: Editorial article
- URL: https://journals.rcsi.science/0040-3660/article/view/31369
- ID: 31369
如何引用文章
详细
Chronic obstructive pulmonary disease (COPD) exacerbations are evaluated from a history of the disease, its clinical symptoms, and laboratory tests. The most common causes of a COPD exacerbation are upper respiratory tract and tracheobronchial infections. The exacerbation severity usually corresponds to the magnitude of clinical manifestations of COPD during its stable course. Successful treatment in patients with a COPD exacerbation is determined by its timely diagnosis. When treating patients with a mild or moderate exacerbation of Stages I-II COPD in an outpatient setting, it is advisable to use ascoril having broncholytic, mucolytic, and mucokinetic properties along with antibiotics and glucocorticosteroids, if clinically indicated.
作者简介
I Leshchenko
Уральская государственная медицинская академия Минздрава России; Медицинское объединение "Новая больница", Екатеринбург
Email: leshchenkoiv@mail.ru
参考
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011). Доступно на: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf
- Anthonisen N.R., Manfreda J., Warren C.P.W. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
- Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698-703.
- Gunen H., Hacievliyagil S.S., Yetkin O. et al. The role of nebulized budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007; 29: 660-667.
- Федосеев Г.Б., Зинакова М.К., Ровкина Е.И. Клинические аспекты применения Аскорила в пульмонологической клинике. Новые Санкт-Петербургские врачебные ведомости 2002; 2: 64-67.
- Ainapure S.S., Desai A., Korde K. Efficacy and safety of Ascoril in the management of cough - National Study Group report. J Indian Med Assoc 2001; 99: 111-114.
- Prabhu Shankar S., Chandrashekharan S., Bolmall C.S., Baliga V. Efficacy, safety and tolerability of salbutamol+guaiphenesin+bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomized controlled comparative study. J Indian Med Assoc 2010; 108: 313-320.
- Jayaram S., Desai A. Efficacy and safety of Ascoril expectorant and other cough formula in the treatment of cough management in paediatric and adult patients - a randomized double-blind comparative trial. J Indian Med Assoc 2000; 98: 68-70.
- Федосеев Г.Б., Орлова Н.Ю., Шалюга Л.В. Применение препарата "АСКОРИЛ" в амбулаторной практике. Новые Санкт-Петербургские врачебные ведомости 2002; 1: 69-70.
- Клячкина Л.М., Дмитриев Ю.К. Лечение нетяжелых обострений хронической обструктивной болезни легких. Клин мед 2012; 3: 79-82.
- Vestbo J., Anderson W., Coxson H.O. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur Respir J 2008; 31: 869-873.
- Agusti A.G., Villaverde J.M., Togores B., Bosch M. ECLIPSE cohort. Respir Res 2010; 11: 122-136.
- Григорьева Н.Ю., Кузнецов А.Н., Королева Т.В., Королева М.Е. Комбинированный препарат аскорил при лечении хронической обструктивной болезни легких с сопутствующей ишемической болезнью сердца. Тер арх 2013; 8: 104-107.
- Клячкина И.Л. Лечение кашля при острой респираторной инфекции и гриппе у пациентов группы риска. Фарматека 2010; 5: 125-132.
补充文件
